News
Three Tips to Stay on Muscarinic Agonists in Sjögren's Disease
Resolution of dryness remains a key unmet need for patients with Sjögren disease (SjD), as highlighted by the Sjögren SIG session “How to treat SjD” on the final day of APLAR 2026. A rheumatology talk in the session noted that recent phase III trials of ianalumab, dazodalibep and telitacicept improved ESSDAI scores, with only some evidence of benefit for dryness itself. Symptomatic care therefore still carries the load. Masafumi Moriyama, DDS, PhD, offered practical insight from the oral health side.
The Concern about Seronegative RA
A current review of seronegative RA (SNRA) by D’Onofrio, et al in npj Autoimmunity shows the diverse fate of seronegative RA - which can resolve, persist or become refractory. Clearly dedicated trials of SNRA are needed to better predict.
Pregnancy in Lupus Nephritis and RA: Managing risks and treating to target
A significant proportion of patients with rheumatologic disease are of reproductive age, therefore, navigating reproductive health is now widely recognized as a fundamental component of modern rheumatology care.
FDA Approves Tildrakizumab for Psoriatic Arthritis
Sun Pharmaceuticals announced Friday that the FDA has approved its IL-23 inhibitor, tildrakizumab (Ilumya) for use in patients with active psoriatic arthritis.
Intra-Articular Injections for Knee OA: Options, Evidence, and no Clear Winner
At APLAR 2026 in Seoul, the OA special interest group offered a whirlwind overview of IA injectables from Dr. Gun-il Im (Dongguk University, Korea). The products fall into three tiers: symptom-modifying, biologic/regenerative and structure-oriented. The pipeline is encouraging, but the evidence is uneven and often thin.
Mixed Drinks, Mixed Results (10.30.2026)
Dr. Cush reviews the news and journal reports from this past week on RheumNow. This week on the podcast: hopeful guidelines for PMR; certainty about good & bad beverages in gout; mixed results in Sjogren's; non-lupus drugs saves lupus lives; and big hips sink ships in psoriatic arthritis.
Does IVIG have a Role in Scleroderma?
Systemic sclerosis, or scleroderma, is one the most challenging rheumatic diseases to manage due to its heterogenous, multisystem manifestations and the limited treatment options for some of its progressive and debilitating complications. Intravenous immunoglobulin (IVIG) is often utilized as an off-label therapy for refractory manifestations. However, evidence guiding usage in SSc remains limited. A recent systemic review and meta-analysis by Jozelio Freire de Carvalho and colleagues analyzed the available literature on this therapy.
Beyond Chondrocalcinosis - What’s New in CPPD Disease
An overview of calcium pyrophosphate deposition (CPPD) disease by Sara Tedeschi presents our evolving understanding of CPPD with advances affecting nomenclature, classification, imaging, genetics, long-term outcomes and potential future targeted therapies. This review builds on other important reports on CPPD.
The Efficacy of Ianalumab in Sjögren’s Disease
The NEPTUNUS-1 and NEPTUNUS-2 trials have showed that monthly ianalumab is superior of placebo at improving Sjögren’s disease activity at week 48, even though there was no significant ESSDAI response or in the change in SSSD or ESSPRI symptom scores.
Menopause Hormone Therapy Tied to Small Autoimmune Disease Risk
MedPage Today
Estrogen-only menopausal hormone therapy was associated with a slightly higher incidence of autoimmune disease compared with estrogen-progestogen therapy, a retrospective cohort study suggested.
2026 BSR Guideline for the Treatment of Polymyalgia Rheumatica
Toyoda and colleagues from the British Society for Rheumatology have published new PMR treatment guidelines to supercede the previously published 2009 BSR/BHPR PMR guidelines. These guidelines emphasize earlier specialist input, methotrexate as an option, and bone protection for all PMR patients who will require chronic glucocorticoids.
Rituximab or Azathioprine for EGPA Maintenance?
A French study has shown that rituximab is more effective than azathioprine at maintaining remission in patients with eosinophilic granulomatosis with polyangiitis (EGPA) on chronic prednisone.
Takayasu Arteritis: Do TNFis or IL-6- inhibitors come out on top?
The treatment of active Takayasu arteritis (TAK) is imperative to quiet vascular inflammation and subsequently maintain vascular integrity while preventing vessel damage.